VTRS Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Viatris Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 11.57 USD 0.87%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast VTRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTRS is 12.39 USD with a low forecast of 10.1 USD and a high forecast of 14.7 USD.

VTRS Lowest Forecast

Wall Street Target

VTRS Average Forecast

Wall Street Target

VTRS Highest Forecast

Wall Street Target

13% Downside

7% Upside

27% Upside

The latest public price target was made on Mar 28, 2024 by David Amsellem from Piper Sandler , who expects VTRS stock to rise by 12% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
David Amsellem Piper Sandler	13 USD Upside 12%	1 month ago Mar 28, 2024	Viatris (VTRS) PT Raised to $13 at Piper Sandler on latest Idorsia deals StreetInsider
David Amsellem Piper Sandler	10 USD Downside 14%	10 months ago Jun 26, 2023	Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts Benzinga
Unknown Analyst Barclays	15 USD Upside 30%	1 year ago Feb 1, 2023	Barclays Maintains Overweight on Viatris, Lowers Price Target to $15 Benzinga

Price Target	13 USD
Upside/Downside	12%

Price Target	10 USD
Upside/Downside	14%

Price Target	15 USD
Upside/Downside	30%

Zhejiang CONBA Pharmaceutical Co Ltd

10% Upside

Kalbe Farma Tbk PT

28% Upside

Bukwang Pharm Co Ltd

374% Upside

Yifan Pharmaceutical Co Ltd

27% Upside

Zhejiang CONBA Pharmaceutical Co Ltd

10% Upside

Kalbe Farma Tbk PT

28% Upside

Bukwang Pharm Co Ltd

374% Upside

Yifan Pharmaceutical Co Ltd

27% Upside

China Chemical & Pharmaceutical Co Ltd

36% Upside

ScinoPharm Taiwan Ltd

4% Downside

Johnson & Johnson

22% Upside

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

132% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Viatris Inc's revenue is 6%. The projected CAGR for the next 3 years is 0%.

6%

0%

-2%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Viatris Inc's operating income is -2%. The projected CAGR for the next 3 years is 42%.

-2%

42%

-51%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Viatris Inc's net income is -29%. The projected CAGR for the next 3 years is 297%.

-29%

297%

-92%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for VTRS is 12.39 USD with a low forecast of 10.1 USD and a high forecast of 14.7 USD.

For the last 8 years the compound annual growth rate for Viatris Inc's revenue is 6%. The projected CAGR for the next 3 years is 0%.

For the last 8 years the compound annual growth rate for Viatris Inc's operating income is -2%. The projected CAGR for the next 3 years is 42%.

For the last 8 years the compound annual growth rate for Viatris Inc's net income is -29%. The projected CAGR for the next 3 years is 297%.

Join more than 132,400+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.